Ra Capital Management, L.p. bought $25M of JANX
director, owner at Janux Therapeutics, Inc.. 824,041 shares at an average of $30.75, traded Mar 5, 2025, filed Mar 7, 2025.
Score components
- +15RoleDirector
- +25Trade size$25.3M at market
- +3Relative to holdingsHoldings up 9%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-007443, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +304,287 | $30.56 | $9.3M | 9,621,533 | Mar 7, 2025 |
| Mar 5, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +37,455 | $31.30 | $1.2M | 9,658,988 | Mar 7, 2025 |
| Mar 6, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +372,093 | $30.78 | $11M | 10,031,081 | Mar 7, 2025 |
| Mar 7, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +110,206 | $31.02 | $3.4M | 10,141,287 | Mar 7, 2025 |
Related signals
Other insiders at Janux Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $107k 3,334 shares | -4% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $141k 3,334 shares | -4% | |
| 27Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $300k 5,000 shares | -2% | |
| 29Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $732k 13,334 shares | -14% | |
| 43Moderate | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.4M 25,000 shares | -10% | |
| 30Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.0M 15,000 shares | -6% | |
| 30Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.3M 25,000 shares | -9% | |
| 38Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.3M 25,000 shares | -8% | |
| 19Weak | JANXsell Janux Therapeutics, Inc. | Jay Lichter owner | $178k 3,815 shares | -35% | |
| 43Moderate | JANXbuy Janux Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $54M 1,200,000 shares | +15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.